Madison have reported a new approach to forming carbon-nitrogen bonds, a critical step in the synthesis of amines widely used ...

For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...

Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease ...

A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis ...

Aaron Wenger is a senior director and principal scientist at Pacific Biosciences, where he oversees the long-read sequencing ...

All Opinion and interviews articles in Drug Target Review ...

The acquisition brings forward a dual-payload antibody-drug conjugate platform originally developed at UTHealth Houston’s McGovern Medical School. The acquisition brings forward a dual-payload ADC ...

A new study has revealed that age-related clonal haematopoiesis accelerates aortic aneurysm growth through RANK/RANKL signalling, meaning that repurposing osteoporosis drugs targeting this pathway ...

NAMs are now part of early drug discovery, but adoption remains uneven. Join leading experts for a discussion on current applications, limitations and what is required for wider use. The session ...

ELRIG is launching its first major US event, Drug Discovery USA 2026, at Pfizer’s Cambridge, Massachusetts facility on 16–17 June. The free-to-attend conference will bring together European and ...

Four Ontario-based research teams will share $3.1 million over two years to develop innovative cancer treatments targeting drug resistance and toxicity. Efforts to improve cancer care are being ...

The new platform enables researchers to analyse gene expression and cellular organisation within intact tissue at single-cell resolution, supporting large-scale studies across fresh-frozen and FFPE ...